Skip to content

Hyperbaric Oxygen Therapy for Optic Neuropathies

A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Neuroprotective Effect of Hyperbaric Oxygen Therapy on Optic Neuropathy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06128720
Acronym
HBOT
Enrollment
60
Registered
2023-11-13
Start date
2022-11-01
Completion date
2027-12-31
Last updated
2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Optic Neuropathy

Brief summary

The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.

Interventions

DEVICEHyperbaric Oxygen

Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen

DEVICESham Hyperbaric Oxygen

Participant will undergo 60 minutes of Sham Hyperbaric Oxygen at atmospheric pressure while breathing room air.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must meet all of the following criteria to join the study (all eligibility criteria must be met at the screening and baseline visits unless otherwise noted): * Participant must be at least 18. * Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE). * Participant's with clinical evidence of optic neuropathy. * Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

Exclusion criteria

* Participant is unable to comply with study procedures or follow-up visits. * Participant has evidence of corneal opacification or lack of optical clarity. * Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration. * Participant is pregnant or lactating. * Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. * Children and comatose patients. * Participant abusing drugs or alcohol. * Prior treatment with hyperbaric oxygen within the last 6 months. * Participant with claustrophobia or that cannot decompress properly.

Design outcomes

Primary

MeasureTime frameDescription
Change in Visual Field- Mean DeviationBaseline through 6 monthsHumphrey visual field testing with standard MD output
Change in Visual Field- Visual Field IndexBaseline through 6 monthsHumphrey visual field testing with standard VFI output

Secondary

MeasureTime frameDescription
Change in Average Thickness Ganglion Cell Complex on Optical Coherence TomographyBaseline through 6 monthsOCT testing with standard GCC output
Change in Average Thickness Retinal Nerve Fiber Layer on Optical Coherence TomographyBaseline through 6 monthsOCT testing with standard RNFL output

Countries

United States

Contacts

Primary ContactZac Wennberg Smith
zacwenn@stanford.edu6504975942

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026